跳至主要内容
临床试验/NCT03837210
NCT03837210已完成2 期

Comparative Anti Helicobacter Pylori Efficacy Assessment of Unani Formulation and Quintuple Regimen

Hamdard University0 个研究点目标入组 300 人开始时间: 2017年1月5日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
300
主要终点
Eradication of H. Pylori

研究概览

简要总结

Helicobacter pylori (H. pylori) is a bacterium its infection is regarded the most common medical condition associated with gastritis1 more over peptic ulcer disease2, gastric adenocarcinoma3 and lymphoma.4control of H pylori infection is thought to be the solution of public health problem.5,6 rate of infection is abating in developed world 7 , but this is slow and people health is challenged, to stop or decrease the new cases is complicated despite the fact that route of transmission are still unclear .8-10 The only option for reducing incidence and prevalence is that screening of masses followed by eradication therapy. A rough estimate propose about 50% of developing country population is affected from infection than the industrialized country. Infected individual may be asymptomatic or some time present with gastroduodenal disease. Prevalence of H pylori is different in developing countries where the adult prevalence reaches up to 80% and in children it is found before the age of 10 years.

详细描述

Helicobacter pylori (H. pylori) is a bacterium its infection is regarded the most common medical condition associated with gastritis1 more over peptic ulcer disease2, gastric adenocarcinoma3 and lymphoma.4control of H pylori infection is thought to be the solution of public health problem.5,6 rate of infection is abating in developed world 7 , but this is slow and people health is challenged, to stop or decrease the new cases is complicated despite the fact that route of transmission are still unclear .8-10 The only option for reducing incidence and prevalence is that screening of masses followed by eradication therapy. A rough estimate propose about 50% of developing country population is affected from infection than the industrialized country. Infected individual may be asymptomatic or some time present with gastroduodenal disease. Prevalence of H pylori is different in developing countries where the adult prevalence reaches up to 80% and in children it is found before the age of 10 years.

Aims and objectives

  1. To establish and evaluate scientific and clinical evidence of herbal/eastern formulation and find out the clinical safety and efficacy.
  2. To measure the clinical response of herbal formulation in the patients of H.Pylori.

Research Questions

  1. has the Unani formulation better effects than quadruple regimen?

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
15 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The individuals suffering from H. pylori infection .
  • Individuals having no previous history of H. pylori infection treatment.
  • Individuals living in Karachi.
  • Individuals with no pathological finding on routine examination.
  • Individuals from either socioeconomic class including lower, middle and higher.
  • Both male and female individuals between 14 to 55 years of age
  • Subjects with informed written consent
  • Patients having no complications regarding other than GIT system.
  • Exclusion Criteria
  • The following were the reason for excluding the individuals from this trial:
  • Patient with simultaneous physical illness, for example renal dialysis and uncontrolled diabetes mellitus.
  • Individuals having stomach or intestinal surgical history were excluded.
  • Individuals with past record of any herbal or allopathic medication were excluded
  • Individuals with hyper sensitivity history of drug or adverse reaction to any of the study drugs .
  • Females with pregnancy were also excluded for the safety measures
  • Individuals with coma, meningitis, and encephalitis or head injury were also excluded.
  • Hospitalized individuals due to any serious diseases were excluded.
  • Individuals with known poor compliance and history of drug abuse were excluded.

排除标准

  • 未提供

研究组 & 干预措施

Test Drug

Experimental

This group is treated with Herbal formulation.

干预措施: Pylorin (Drug)

Control Drug

Active Comparator

This group is treated with Quintuple therapy

干预措施: Pylorin (Drug)

结局指标

主要结局

Eradication of H. Pylori

时间窗: 4 week duration

Negative Stool antigen for H. pylori

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Syed Zahoor Ul Hassan Zaidi

Syed Zahoor Ul Hassan Zaidi

Hamdard University

相似试验

Comparative Anti Helicobacter Pylori Efficacy... | 临床试验